Bristol-Myers Squibb and Celgene Merger Overview (2019)
CASE 7 Bristol-Myers Squibb and Celgene Merger Overview (2019) 1. Announcement and Motivation: - The merger between Bristol-Myers Squibb (BMS) and Celgene was announced in January 2019. - The deal was valued at approximately $74 billion, making it one of the largest mergers in the pharmaceutical industry. 2. Companies Involved: - Bristol-Myers Squibb (BMS): A global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines for serious diseases. - Celgene: A biopharmaceutical company known for its expertise in hematology and oncology, particularly in the development of cancer therapies. 3. Purpose and Strategic Rationale: - The merger aimed to create a leading biopharmaceutical company with a strong presence in oncology, immunology, and cardiovascular disease. - BMS sought to enhance its pipeline and portfolio of innovative drugs, partic...